See the DrugPatentWatch profile for jornay
Journay does not currently have a generic version available [1].
When might a generic version of Journay become available?
The availability of a generic version of Journay hinges on the expiration of its patents and any associated market exclusivity periods. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate potential timelines for generic entry [1].
What is Journay?
Journay is a prescription medication used to treat moderate to severe plaque psoriasis [1].
How does Journay work?
Journay is a selective and reversible inhibitor of Janus kinase 1 (JAK1) [1]. By inhibiting JAK1, it impacts signaling pathways involved in inflammation and immune responses that contribute to psoriasis [1].
What are the risks associated with Journay?
Like other JAK inhibitors, Journay carries certain risks. These include serious infections, increased risk of death, cardiovascular events, thrombosis, and malignancy [1]. Patients should discuss these risks thoroughly with their healthcare provider.
Are there other treatments for plaque psoriasis?
Yes, there are other treatment options for plaque psoriasis, including topical medications, phototherapy, and other systemic therapies, such as other JAK inhibitors, biologics, and conventional immunosuppressants [1]. The choice of treatment depends on the severity of the psoriasis and individual patient factors.